Suprachoroidal gene transfer with nonviral nanoparticles
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Suprachoroidal gene transfer with nonviral nanoparticles provides noninvasive transgene expression in photoreceptors and RPE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Widespread expression of GFP in retina and RPE 2 months after suprachoroidal injection of NPs containing a CMV-GFP expression plasmid. Brown Norway rats were given a 3-μl suprachoroidal injection of PBAE NPs containing 1 μg of CMV-GFP expression plasmid 1 mm posterior to the limbus in the inferonasal quadrant near the vertical meridian (A). Two months after injection, rats were euthanized, eyes were frozen in embedding medium, and transverse sections were immunohistochemically stained for GFP, counterstained with Hoechst, and merged with its fluorescent image. In the inferior (B), temporal (C), superior (D), and nasal (E) meridians of a section 600 μm posterior to the limbus through anterior retina [intersections of inner surface of blue ring and white lines in (A)], there was colocalization of fluorescence with anti-GFP staining in RPE and photoreceptor inner and outer segments. At the inferior (F), temporal (G), superior (H), and nasal (I) meridians of a section 1800 μm posterior to the limbus through posterior retina, staining for GFP in RPE and photoreceptor inner and outer segments was similar to that seen in anterior retina. Occasional weak expression of GFP was seen in cells of the inner retina (arrows). Scale bar, 100 μm.](https://figures.cochat.ai/paper-figures/621bb6ef7c144529bc1bc9609e0fce89/suprachoroidal-gene-transfer-with-nonviral-nanoparticles-figure-2.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This route is also being investigated for delivering non-viral vectors with promising results in animals.94”
From Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses (2022) · cites this paper as [94]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Barua, S., & Mitragotri, S. (2014) · Nano Today · doi:10.1016/j.nantod.2014.04.008 · Cited by 1,257 · cited 1×
“While diffusion of polymeric NPs in tissue has been previously documented ( 32 ), the lateral and radial penetration of PBAE NPs from the suprachoroidal space is most likely due to a transient pressure increase that is induced by the introduced volume into a confined space ( 33 ).”
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Dalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734 · cited 1×
“In vivo–directed evolution has resulted in new AAV vectors with reduced binding to the ILM that penetrate further into the retina after intravitreous injection, resulting in widespread transduction of photoreceptors and no inflammation in rodents; however, in nonhuman primates, intravitreous injection of these vectors…”
A combinatorial polymer library approach yields insight into nonviral gene delivery
Green, J. J., Langer, R., & Anderson, D. G. (2008) · Accounts of Chemical Research · doi:10.1021/ar7002336 · Cited by 579 · cited 2×
“Cationic poly(-amino ester)s (PBAEs) with primary, secondary, and tertiary amines and hydrolytically cleavable ester bonds compact DNA into positively charged nanoparticles (NPs) that undergo endocytosis and endosomal escape (17, 18).”
Self-citationBennett, J., Wellman, J., Marshall, K. A., McCague, S., Ashtari, M., DiStefano-Pappas, J., Elci, O. U., Chung, D. C., Sun, J., Wright, J. F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30371-3 · Cited by 461
VEGF is major stimulator in model of choroidal neovascularization.
Kwak, N., Okamoto, N., Wood, J. M., & Campochiaro, P. A. (2000) · PubMed · Cited by 442
Self-citationOkamoto, N., Tobe, T., Hackett, S. F., Ozaki, H., Vinores, M. A., La Rochelle, W., Zack, D. J., & Campochiaro, P. A. (1998) · Retina · doi:10.1097/00006982-199805000-00034 · Cited by 365 · cited 3×
“An expression plasmid for VEGF (pVEGF) was generated by excising EGFP (enhanced GFP) from pEGFP-N1 and replacing it with the coding sequence for VEGF165 excised from pRho-hVEGF (30).”
InfluentialSelf-citation
Cited by
The effects of PEGylation on LNP based mRNA delivery to the eye
Ryals, R. C., Patel, S., Acosta, C., McKinney, M., Pennesi, M. E., & Sahay, G. (2020) · PLOS ONE · doi:10.1371/journal.pone.0241006 · Cited by 194
Strategies for non-viral vectors targeting organs beyond the liver
Kim, J., Eygeris, Y., Ryals, R. C., Jozić, A., & Sahay, G. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01563-4 · Cited by 173
“Spleen-targeting PBAE NPs were cationic with a hydrodynamic size less than 100 nm (ref.”
InfluentialSelf-citationGautam, M., Jozic, A., Su, G. L.-N., Herrera-Barrera, M., Curtis, A., Arrizabalaga, S., Tschetter, W., Ryals, R. C., & Sahay, G. (2023) · Nature Communications · doi:10.1038/s41467-023-42189-3 · Cited by 123
Review of gene therapies for age-related macular degeneration
Khanani, A. M., Thomas, M. J., Aziz, A. A., Weng, C. Y., Danzig, C. J., Yiu, G., Kiss, S., Waheed, N. K., & Kaiser, P. K. (2022) · Eye · doi:10.1038/s41433-021-01842-1 · Cited by 119
“Because the suprachoroidal space is adjacent to the high blood flow of the choroid, injecting formulations with larger particle size such as a steroid emulsion, viral particles, or nanoparticles are necessary to avoid rapid egress from the suprachoroidal space [55].”
BackgroundOcular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses
Ghoraba, H. H., Akhavanrezayat, A., Karaca, I., Yavari, N., Lajevardi, S., Hwang, J., Regenold, J., Matsumiya, W., Pham, B., Zaidi, M., et al. (2022) · Clinical Ophthalmology · doi:10.2147/opth.s364200 · Cited by 76
“This route is also being investigated for delivering non-viral vectors with promising results in animals.(94) Different techniques are being used for suprachoroidal drug delivery.”
BackgroundHancock, S. E., Wan, C.-R., Fisher, N. E., Andino, R. V., & Ciulla, T. A. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1867532 · Cited by 74
“The SCS has also been accessed using a standard hypodermic needle [30,31].”
MethodDrug delivery via the suprachoroidal space for the treatment of retinal diseases
Naftali Ben Haim, L., & Moisseiev, E. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13070967 · Cited by 68
“[104] reported the results of SC injections of nano particles (NPs) containing different plasmids to rats.”
BackgroundSuprachoroidal Injection: A Novel Approach for Targeted Drug Delivery
Wu, K. Y., Fujioka, J. K., Gholamian, T., Zaharia, M., & Tran, S. D. (2023) · Pharmaceuticals · doi:10.3390/ph16091241 · Cited by 69
“GFP, fluorescence not strong enough to be visualized on flat mounts; multiple injections markedly increase expression; expression maintained without substantial decline at least through 8 months -Neovascularization after SC injection of NPs containing VEGF expression plasmid: severe subretinal neovascularization start…”
BackgroundInfluentialWan, C.-R., Muya, L. W., Kansara, V. S., & Ciulla, T. A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020288 · Cited by 69
“VEGFexpressing plasmid NP Nonviral vector gene therapy Disease model for nAMD Preclinical (Rat) 5 months Severe neovascularization and subsequent subretinal fibrosis were observed at 1 and 5 months, respectively [87]”
BackgroundMethodInfluentialGenome editing in the treatment of ocular diseases
Choi, E. H., Suh, S., Sears, A. E., Hołubowicz, R., KEDHAR, S. R., Browne, A., & Palczewski, K. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01057-2 · Cited by 57
Six-month sustained delivery of anti-VEGF from in-situ forming hydrogel in the suprachoroidal space
Jung, J. H., Kim, S. S., Chung, H., Hejri, A., & Prausnitz, M. R. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.10.036 · Cited by 48
Toward Gene Transfer Nanoparticles as Therapeutics
Kavanagh, E. W., & Green, J. J. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202102145 · Cited by 48
Self-citationKim, J., Vaughan, H. J., Zamboni, C. G., Sunshine, J. C., & Green, J. J. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.047 · Cited by 44
Self-citationDose‐Independent Transfection of Hydrophobized Polyplexes
Zhang, Z., Qiu, N., Wu, S., Liu, X., Zhou, Z., Tang, J., Liu, Y., Zhou, R., & Shen, Y. (2021) · Advanced Materials · doi:10.1002/adma.202102219 · Cited by 42
Advances in ophthalmic optogenetics: approaches and applications
Prosseda, P. P., Tran, M., Kowal, T., Wang, B., & Sun, Y. (2022) · Biomolecules · doi:10.3390/biom12020269 · Cited by 41
“Further, biodegradable poly(β-amino ester) nanoparticle-based delivery of a plasmid encoding vascular endothelial growth factor (VEGF) neutralizing protein, p3sF1t1Fc, significantly suppressed vascular leakage and neovascularization in a mouse model of wet age-related macular degeneration (AMD) [36].”
BackgroundInfluentialFostering the unleashing potential of nanocarriers-mediated delivery of ocular therapeutics
Datta, D., Bandi, S. P., Colaco, V., Dhas, N. L., Reddy, D. S., & Vora, L. K. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124192 · Cited by 40
Salman, A., Kantor, A., McClements, M. E., Marfany, G., Trigueros, S., & MacLaren, R. E. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091842 · Cited by 37
Toward low-cost gene therapy: mRNA-based therapeutics for treatment of inherited retinal diseases
Antas, P., Carvalho, C., Cabral-Teixeira, J., de Lemos, L., & Seabra, M. C. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.11.009 · Cited by 36
Looking into the future: Gene and cell therapies for glaucoma
Komáromy, A. M., Koehl, K. L., & Park, S. A. (2021) · Veterinary Ophthalmology · doi:10.1111/vop.12858 · Cited by 33
What’s New in Ocular Drug Delivery: Advances in Suprachoroidal Injection since 2023
Wu, K. Y., Gao, A., Giunta, M., & Tran, S. D. (2024) · Pharmaceuticals · doi:10.3390/ph17081007 · Cited by 30
“For SC injections, key considerations include drug distribution within the SCS (anterior vs. posterior), across the eye (anterior vs. posterior segments, within specific ocular layers), and clearance.”
BackgroundNanoparticle-mediated gene therapy as a novel strategy for the treatment of retinoblastoma
Mandal, M., Banerjee, I., & Mandal, M. (2022) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2022.112899 · Cited by 28
Enhanced nuclear gene delivery via integrating and streamlining intracellular pathway
Qi, L., Wang, Y., Hu, L., Zhao, P.-S., Yu, H., Xing, L., Gao, X., Cao, Q., & Jiang, H. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.046 · Cited by 27
Kansara, V. S., Cooper, M. J., Sesenoglu‐Laird, O., Muya, L. W., Moen, R. C., & Ciulla, T. A. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.13.21 · Cited by 25
Potential of miRNA-Based Nanotherapeutics for Uveal Melanoma
Yang, C., Wang, R., & Hardy, P. (2021) · Cancers · doi:10.3390/cancers13205192 · Cited by 24
Suprachoroidal gene transfer with nonviral nanoparticles in large animal eyes
Shen, J., Silva, R. L. E., Zhang, M., Luly, K. M., Hackett, S. F., Tzeng, S. Y., Lowmaster, S. M., Shannon, S. R., Wilson, D. R., Green, J. J., et al. (2024) · Science Advances · doi:10.1126/sciadv.adl3576 · Cited by 23
“In previously reported experiments ( 9 ), suprachoroidal injections were done with a commercially available 4733-bp GFP expression plasmid, pEGFP-N1 , in which the cytomegalovirus (CMV) promoter drives expression of GFP.”
InfluentialSelf-citationUpdates on Emerging Interventions for Autosomal Recessive ABCA4-Associated Stargardt Disease
Wang, L., Shah, S. M., Mangwani‐Mordani, S., & Gregori, N. Z. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196229 · Cited by 23
“Upcoming pre-clinical studies are evaluating non-viral delivery systems such as covalently closed and circular DNA (C3DNA) and nanoparticles [22,23].”
Novel Approaches in the Drug Development and Delivery Systems for Age-Related Macular Degeneration
Paliwal, H., Prajapati, B. G., Srichana, T., Singh, S. K., & Patel, R. J. (2023) · Life · doi:10.3390/life13020568 · Cited by 22
Immunology of Retinitis Pigmentosa and Gene Therapy–Associated Uveitis
Yang, P. G., Mustafi, D., & Pepple, K. L. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041305 · Cited by 22
Gene and cell therapy for age-related macular degeneration: A review
Trincão-Marques, J., Ayton, L. N., Hickey, D. G., Marques‐Neves, C., Guymer, R. H., Edwards, T. L., & Sousa, D. C. (2024) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2024.05.002 · Cited by 25
Gibson, V. P., Derbali, R. M., Phan, H. T., Tahiri, H., Allen, C. J., Hardy, P., & Chain, J. L. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119824 · Cited by 17
Hu, D., Zhang, R., Yao, S., Iacob, C. E., Yang, W., Rosen, R. B., & Yang, S. (2021) · Current Eye Research · doi:10.1080/02713683.2021.1929326 · Cited by 15
Progressing nanotechnology to improve diagnosis and targeted therapy of Diabetic Retinopathy
Baghban, R., Namvar, E., Attar, A., & Mortazavi, M. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117786 · Cited by 13
Chiang, B., Chung, Y. G., & Prausnitz, M. R. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.04.020 · Cited by 13
Biodegradable Polyester Nanoparticle Vaccines Deliver Self‐Amplifying mRNA in Mice at Low Doses
Wilson, D. R., Tzeng, S. Y., Rui, Y., Neshat, S. Y., Conge, M., Luly, K. M., Wang, E. B., Firestone, J. L., McAuliffe, J., Maruggi, G., et al. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202200219 · Cited by 13
Self-citationShining light on CRISPR/Cas9 therapeutics for inherited retinal diseases
Geiger, A., Kennedy, J. G., Staker, L. G., Wensel, T. G., Casson, R. J., & Thomas, P. Q. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101376 · Cited by 11
Tang, M., Zhang, L., Song, B., Ji, X., Wang, C., Wang, H., Xu, H., Su, Y., & He, Y. (2021) · Nano Research · doi:10.1007/s12274-021-3302-6 · Cited by 11
Childhood-onset genetic cone-rod photoreceptor diseases and underlying pathobiology
Garafalo, A. V., Sheplock, R., Sumaroka, A., Román, A. J., Cideciyan, A. V., & Jacobson, S. G. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2020.103200 · Cited by 10
“The delivery method also needs to be considered; intravitreal gene delivery is being developed as an alternative to subretinal gene delivery for some IRDs and should be considered for diseases with already fragile foveas, as in BCM or ACHM [70], and there are advances in suprachoroidal gene transfer [73].”
MethodSurgical Approaches to Retinal Gene Therapy: 2025 Update
Patel, M. J., Sheth, S., Mar, J., Gregori, N. Z., & Sengillo, J. D. (2025) · Bioengineering · doi:10.3390/bioengineering12101122 · Cited by 12
“In rat eyes, supra-choroidal injection of PBAEs enabled sustained GFP expression in the retina for at least 6 months, with broader biodistribution than intravitreal or subretinal delivery, and, while achieving lower overall expression than AAV8, it could be enhanced with repeated injections [53].”
Lim, Y., Campochiaro, P. A., & Green, J. J. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.12.010 · Cited by 10
Self-citationGenetic engineering and the eye
Murphy, R., & Martin, K. R. G. (2024) · Eye · doi:10.1038/s41433-024-03441-2 · Cited by 9
Advances in locally administered nucleic acid therapeutics
Shen, J., Duan, X., Xie, T., Zhang, X., Cai, Y., Pan, J., Zhang, X., & Sun, X. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.02.043 · Cited by 17
Self-citationA Novel Device for Suprachoroidal Drug Delivery to Retina: Evaluation in Nonhuman Primates
Rotenstreich, Y., Sher, I., Lawrence, M. S., Mangelus, M., Ingerman, A., & Barak, Y. (2023) · Translational Vision Science & Technology · doi:10.1167/tvst.12.6.3 · Cited by 8
Huang, X., Zhang, L., Fu, Y., Zhang, M., Yang, Q., & Peng, J. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1199922 · Cited by 7
Hua, Z., Shen, Y., & Zhou, X. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18030282 · Cited by 5
“It allows precise delivery to choroidal tissue while maintaining a minimally invasive profile [162–164].”
Kureshi, R., Zhu, A. Y., Shen, J., Tzeng, S. Y., Astrab, L. R., Sargunas, P. R., Green, J. J., Campochiaro, P. A., & Spangler, J. B. (2020) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-020-00641-0 · Cited by 5
Self-citationHow Advanced are Nanocarriers for Effective Subretinal Injection?
Guan, J.-X., Wang, Y.-L., & Wang, J. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s479327 · Cited by 5
“61 Moreover, nanocarriers can be easily modified to include targeted transport, which can increase the drug concentration in target cells or tissues, minimize unnecessary dilution and wastage, and reduce drug side effects.”
BackgroundSelf-citationApplication Prospects for Synthetic Nanoparticles in Optogenetic Retinal Prosthetics
Rotov, A. Y., Romanov, I. S., Tarakanchikova, Y. V., & Astakhova, L. A. (2021) · Journal of Evolutionary Biochemistry and Physiology · doi:10.1134/s0022093021060132 · Cited by 4
“The PLGA related compounds, polyaminoesters, are also used as a basis for nanovehicles, having an advantage in DNA binding due to the presence of cationic amino groups [94].”
BackgroundBench-to-Bedside Research in Ophthalmology
Gupta, A. (2022) · Springer eBooks · doi:10.1007/978-981-16-8845-4_5 · Cited by 5
Optogenetics: A Novel Therapeutic Avenue for Age-Related Macular Degeneration
Grenga, P., Ciancimino, C., Meduri, A., & Fragiotta, S. (2025) · Biomolecules · doi:10.3390/biom15091286 · Cited by 3
Lee, D., Kwak, G., Johnson, T. V., & Suk, J. S. (2022) · Current Protocols · doi:10.1002/cpz1.607 · Cited by 2
“As such, an increasing number of preclinical studies evaluating synthetic nucleic acid delivery platforms for ocular applications are being reported (Ryals et al., 2020; Shen et al., 2020; Wang, Rajala, & Rajala, 2018; Zulliger et al., 2018).”
BackgroundZhang, M., Shen, J., Luly, K. M., Lim, Y., Shannon, S. R., Jain, M., Tzeng, S. Y., Hackett, S. F., Kanan, Y., Green, J. J., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118711 · Cited by 2
Self-citationGiudice, G. L., Galan, A., & Gattazzo, I. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.112174 · Cited by 2
Nork, T. M., Katz, A. W., Rasmussen, C. A., Kim, C. B. Y., Sonnentag, P. J., & Murphy, C. J. (2025) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1177/10807683251366799 · Cited by 1
Zhang, D., Zhu, Q., Huang, R., Zhuang, A., & Zhu, D. (2025) · European Journal of Ophthalmology · doi:10.1177/11206721251379936 · Cited by 1
“13,14 The US Food and Drug Administration recently approved the SCS Microinjector ® (Clearside Microinjector, Alpharetta, GA) for the vertical injection of a triamcinolone acetonide (TA) suspension into the SCS at the pars plana.”
Visual Neurorestoration: An Expert Review of Current Strategies for Restoring Vision in Humans
Cavaleri, J., Lin, M. P., Wu, K., Gilbert, Z. D., Huang, C. Y., Lo, Y. T., Garimella, V., Dallas, J., Briggs, R. G., Borja, A. J., et al. (2025) · Brain Sciences · doi:10.3390/brainsci15111170 · Cited by 1
George, A., Leigh, A., Selzer, E. B., Pfister, T., DeYoung, C., Villasmil, R., Abu-Asab, M. S., Hiriyanna, S., Hwang, P., Sharma, R., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201705 · Cited by 1
“30 Additionally, viral injection into the vitreous cavity results in a significant humoral immune response when compared to sub-retinal injection.”
Chen, M., Jiao, W., Liu, T., & Zhao, B. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1797383 · Cited by 1
“Although cost-eective, this approach requires substantial operator skills to avoid adverse events such as scleral perforation and subretinal injection (61, 62).”
Administration of Ocular Gene Therapy
Xu, D. N., Khan, M., Klufas, M. A., & Ho, A. C. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000365 · Cited by 1
Role of miRNA in adult ocular tumorigenesis
Romani, A., Melloni, E., Lodi, G., Bompan, F., Foschi, R., Zauli, E., Pozza, E., Secchiero, P., Zauli, G., Previati, M., et al. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1459761
“Consistently, Shen et al. observed that nanoparticle-mediated gene transfer via suprachoroidal route warranted long gene expression times in a safe and repeatable manner (Shen et al., 2020).”
Evolutionary tuning of rhodopsin-mediated light protectionPreprint
Dbouk, N. H., Bagshaw, M., Bose, A. A., Arner, A., Zhao, K., Praveen, N., Bautista, I., Musayeva, N., Xue, L., McElhinney, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.05.722510
Stem cell therapy in retinal disease
WANG, J., Felfeli, T., & Ballios, B. G. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-443-22212-2.00004-5
Self-citationStem Cell Therapy for Inherited Retinal Disorders: Rebuilding the Retina
Garg, A., & Ahmed, I. (2026) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2026.07.033
Hollow Microneedles in Ophthalmology: From Drug Delivery to Integrated Biosensing
Sun, F., Xiao, C., Wang, Z., Hu, W., Peng, Z., Wong, Z. J., Tan, Z., & Cui, B. (2026) · Small · doi:10.1002/smll.75520
Metadata
- Authors
- Shen, J., Kim, J., Tzeng, S. Y., Ding, K., Hafiz, Z., Long, D., Wang, J., Green, J. J., & Campochiaro, P. A.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Green, Jordan J.
- Campochiaro, Peter A.
- ORCID
- Venue
- Science Advances
- Published
- 2020-07-03
- Volume
- 6
- Issue
- 27
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC7458446
- OpenAlex
- W3039061026
- Cited by
- 63
- References
- 40
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 7 · 2023: 12 · 2022: 9 · 2021: 13 · 2020: 4
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Science Advances (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (R21EY026148, R01EY028996, R01EB022148)
- National Eye Institute (EY01765, RO1EY031097)
- Research to Prevent Blindness
- James and Carole Free Catalyst Award
- Barth Foundation (none)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- biodegradable nanoparticles, subretinal injection, vascular endothelial growth factor, neovascular age-related macular degeneration, subretinal neovascularization, subretinal fibrosis, photoreceptors, retinal pigment epithelium, reporter plasmid, vascular leakage
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.